Mahamaya Lifesciences Ltd

Mahamaya Lifesciences Ltd

$MAHALIFEEquityBSE

Mahamaya Lifesciences Ltd (MAHALIFE) last traded at ₹197, a market capitalisation of ₹461 crore, on a P/E of 27.9. Over the past 52 weeks the stock has ranged between ₹111 and ₹205. Mahamaya Lifesciences Ltd last reported results for the quarter ended Mar 2026, with sales of ₹166 crore and net profit of ₹8 crore. Mahamaya Lifesciences Ltd’s annual general meeting is scheduled for 29 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.

Mahamaya Lifesciences Ltd share price and key metrics

Current price
₹197
Market cap
₹461 cr
Stock P/E
27.9
Book value
₹52.1
ROE
19.3%
ROCE
20.0%
Dividend yield
0.00%
52w high / low
205/111

Metrics as of 25 Aug 2026. Not real time.

Mahamaya Lifesciences Ltd quarterly results

Mahamaya Lifesciences Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Sep 2025Mar 2026
Sales146163166
Expenses133148149
Operating profit131517
OPM %9%9%10%
Other income111
Interest444
Depreciation111
Profit before tax101112
Tax %27%27%35%
Net profit788
EPS (₹)4.084.713.48

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Mahamaya Lifesciences Ltd annual results

Mahamaya Lifesciences Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales90137161264329
Operating profit69132334
OPM %7%6%8%9%10%
Net profit3451317
EPS (₹)21.7830.0341.807.287.06

TTM is the trailing twelve months to the most recent quarter.

Mahamaya Lifesciences Ltd growth and returns

Compounded Sales Growth
10 Years
%
5 Years
%
3 Years
34%
TTM
25%
Compounded Profit Growth
10 Years
%
5 Years
%
3 Years
64%
TTM
28%
Stock Price CAGR
10 Years
%
5 Years
%
3 Years
%
1 Year
%
Return on Equity
10 Years
%
5 Years
23%
3 Years
24%
Last Year
19%

Mahamaya Lifesciences Ltd shareholding pattern

Promoters held 56.35% at Mar 2026, broadly unchanged since Nov 2025. FIIs 4.77% and DIIs 2.52%.

Mahamaya Lifesciences Ltd shareholding pattern by quarter, in percent
% heldNov 2025Mar 2026
Promoters56.35%56.35%
FIIs6.39%4.77%
DIIs4.67%2.52%
Public32.60%36.35%
No. of shareholders1,034584

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

When is Mahamaya Lifesciences Ltd’s AGM?

Mahamaya Lifesciences Ltd’s annual general meeting is scheduled for 29 Sept 2026.

  • AGM24th Annual General Meeting

See the full results calendar for every Indian company reporting in the next 30 days.

Mahamaya Lifesciences Ltd corporate filings

  • Appointment of Mr. Kush Mishra as Company Secretary and Compliance OfficerCompany Updatemedium impact
    Filing PDF

    Cruxal's analysis: Mahamaya Lifesciences Limited has announced a significant leadership transition effective…

    Read the full analysis
  • Investor Presentation to be shared during Investor Meet scheduled to be held on 07th August, 2026Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Mahamaya Lifesciences Limited has filed an intimation regarding an investor presentation…

    Read the full analysis
  • Intimation of Schedule of Analyst(s) /Investor(s) meetingCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Mahamaya Lifesciences Ltd. has announced the intimation of a schedule for an upcoming…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Mahamaya Lifesciences Ltd

Cruxal reads every Mahamaya Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.

Mahamaya Lifesciences Ltd (MAHALIFE) Results, Financials & Share Price | Cruxal